We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
All stakeholders involved in U.S. Food and Drug Administration-regulated clinical trials should begin now to plan for transitioning to use of informed consents that meet the specific requirements of the new rule
